The PD-1/PD-L1 blockade has been revolutionary in cancer immunotherapy, and it has been used in the treatment of numerous malignancies, including melanoma, hepatocellular carcinoma, breast cancer, and Hodgkin’s lymphoma [69]. Here, CD274 is linked to Hodgkins lymphoma.